PRAME Antibody (Rabbit mAb) [B12N21]

製品コード:F7504

印刷

生物学的記述

Specificity PRAME Antibody (Rabbit mAb) [B12N21] detects endogenous levels of total PRAME proteins.
Background PRAME (preferentially expressed antigen in melanoma) is a leucine-rich repeat protein of the cancer/testis antigen family, normally restricted in expression to the testis, ovary, placenta and a few other tissues, that functions as a dominant repressor of retinoic acid receptor (RAR) signaling. PRAME binds RAR specifically in the presence of retinoic acid, and rather than allowing this ligand-bound receptor to activate transcription of its target genes as it normally would, PRAME instead prevents this ligand-induced activation and recruits Polycomb group proteins to RAR target gene promoters, converting retinoic acid-bound RAR from a transcriptional activator into a repressed complex; PRAME is directly present at these RAR target promoters, and RNA interference-mediated knockdown of PRAME in retinoic acid-resistant human melanoma restores normal RAR signaling and reinstates sensitivity to retinoic acid's antiproliferative effects both in cultured cells and in vivo, demonstrating that PRAME's repressive activity is directly responsible for blocking retinoic acid-induced growth arrest, differentiation and apoptosis rather than being a bystander marker of the resistant state. Beyond solid tumors, PRAME's function was independently characterized in hematopoietic cells, where forced expression of PRAME in normal hematopoietic progenitors inhibits myeloid differentiation both in the presence and absence of retinoic acid, while in leukemia cell lines PRAME's inhibitory effect on granulocytic differentiation is restricted specifically to cell lines that normally differentiate along the granulocytic lineage in response to retinoic acid exposure; silencing PRAME in primary chronic myeloid leukemia (CML) progenitor cells reverses this differentiation block, and PRAME mRNA levels rise as CML disease progresses, with its detection in late chronic-phase CML patients before starting tyrosine kinase inhibitor therapy predicting poorer treatment response. This pattern demonstrates that PRAME's capacity to block differentiation is dependent on the specific lineage and differentiation pathway of the cell in which it is expressed rather than acting as a universal, cell type-independent repressor. Because PRAME is broadly overexpressed across many cancers, including melanoma and various leukemias, while remaining essentially undetectable in most normal adult tissues, it is used both as a diagnostic and prognostic biomarker and as a target for antigen-specific T cell-based cancer immunotherapy.

使用情報

Application WB, IHC, FCM Dilution
WB IHC FCM
1:1000 1:100-1:400 1:400-1:1600
Reactivity Human
Source Rabbit Monoclonal Antibody MW 58 kDa
Storage Buffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Storage
(from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 120 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use primary antibody dilution buffer to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
IHC
Experimental Protocol:
 
Deparaffinization/Rehydration
1. Deparaffinize/hydrate sections:
2. Incubate sections in three washes of xylene for 5 min each.
3. Incubate sections in two washes of 100% ethanol for 10 min each.
4. Incubate sections in two washes of 95% ethanol for 10 min each.
5. Wash sections two times in dH2O for 5 min each.
6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
 
Staining
1. Wash sections in dH2O three times for 5 min each.
2. Incubate sections in 3% hydrogen peroxide for 10 min.
3. Wash sections in dH2O two times for 5 min each.
4. Wash sections in wash buffer for 5 min.
5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
9. Wash sections three times with wash buffer for 5 min each.
10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
12. Immerse slides in dH2O.
13. If desired, counterstain sections with hematoxylin.
14. Wash sections in dH2O two times for 5 min each.
15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
16. Mount sections with coverslips and mounting medium.
 

References

  • https://pubmed.ncbi.nlm.nih.gov/16179254/
  • https://pubmed.ncbi.nlm.nih.gov/19625708/

Application Data

WB

Validated by Selleck

  • F7504-wb.gif
    Lane 1: K562, Lane 2: OVCAR3